Arrowhead Research reported $824.07M in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
Ligand Pharmaceuticals USD 1.13B 679.7M Jun/2026
Merck USD 49.69B 1.39B Sep/2026
Moderna USD 3.55B 2.95B Sep/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Novartis USD 38.38B 893M Sep/2026
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
TG Therapeutics USD 745.63M 247K Sep/2026
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026
Xencor USD 71.93M 5.61M Sep/2026